The Company makes certain filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission (the “SEC”), all of which are available under our profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. For a more complete discussion of the risk factors affecting our business, please refer to these filings.
Our public communications, including this media page, SEDAR+ and SEC filings may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based upon current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties. These forward-looking statements often, but not always, may be identified by the use of words such as “believes,” “estimates,” “anticipates,” “targets,” “expects,” “plans,” “projects,” “intends,” “predicts,” “may,” “could,” “might,” “will,” “should,” “approximately,” “potential” or, in each case, their negative or other variations thereon or comparable terminology, although not all forward-looking statements contain these words. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
These forward-looking statements appear in a number of places throughout this media page and include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, our reliance on third parties to carry out a large portion of our business; the possibility that pre-clinical and initial clinical trials will not necessarily be predictive of future results; our ability to obtain additional capital to continue our operations; our reliance on key personnel; our success in completing the development of our products, commercializing our products or generating significant revenues; our ability to successfully develop, maintain and protect our proprietary products and technologies; and potential difficulties recruiting or retaining patients in our ongoing and planned clinical trials. These statements are also subject to other risks and uncertainties as further detailed in the Company’s most recently filed periodic report, and subsequent periodic reports filed by the Company, under the Securities Exchange Act of 1934, as amended, any of which could cause actual results to differ materially from those contained in or implied by the forward-looking statements in this media page.
By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics, and healthcare, regulatory and scientific developments and depend on the economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated or not at all. Although we believe that we have a reasonable basis for each forward-looking statement contained in this media page, we caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this media page.
To the extent any forward-looking statements in this media page constitutes “future-oriented financial information” or “financial outlooks” within the meaning of applicable Canadian securities laws, such information is being provided to assist readers in understanding management’s current expectations and the reader is cautioned that this information may not be appropriate for any other purpose and the reader should not place undue reliance on such future-oriented financial information and financial outlooks. Future-oriented financial information and financial outlooks, as with forward-looking information generally, are, without limitation, based on the assumptions and subject to the risks set out herein. The Company’s actual financial position and results of operations may differ materially from management’s current expectations and, as a result, the Company’s revenue and expenses may differ materially from the revenue and expenses profiles provided in this media page. The Company does not undertake any obligation to update any forward-looking statements contained in this media page unless required by applicable law.
BriaCell virtual investor presentation – Thursday, June 12, 2025
2025 June – Oncology Central –ASCO insights: Bria-IMT + checkpoint inhibitor trials in metastatic breast cancer
Dr. Carmen Calfa, Principal Clinical Investigator of the Phase 2 Bria-IMT study, is featured to discuss BriaCell Poster presentation at ASCO25 which highlighted survival results for Bria-IMT + checkpoint inhibitors for metastatic breast cancer (MBC) patients
2024 Oct – OncLive – Bria-IMT Plus Immunotherapy Shows Early Promise in Breast Cancer Brain Metastasis
Dr. Giuseppe Del Priore, BriaCell’s CMO, and Dr. William V. Williams, BriaCell’s CEO, are featured to discuss BriaCell reporting of 100% Resolution of brain metastasis in breast cancer patient with “eye-bulging” tumor
2024 Sept – OncLive – BRIA-ABC Trial Explores Novel Post-ADC Strategy for Metastatic Breast Cancer
Principal Investigator, and Professor of Oncology, Mayo Clinic, Saranya Chumsri, MD, and BriaCell’s Medical Advisory Board Member, and Professor of Medicine at the University of Pittsburgh School of Medicine, Adam M. Brufsky, MD, PhD, discuss the evaluation of Bria-IMT plus a checkpoint inhibitor in metastatic breast cancer
BriaCell’s Medical Advisory Board Member, Dr. Adam M. Brufsky, MD, PhD, FACP, discusses the unique design of the allogeneic GM-CSF–secreting breast cancer vaccine SV-BR-1-GM
